CPP (Cancer Prevention Pharmaceuticals) Enterprise Value : $0.00 Mil (As of Jun. 15, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cancer Prevention Pharmaceuticals's Enterprise Value is $0.00 Mil. Cancer Prevention Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2016 was $-3.98 Mil. Therefore, Cancer Prevention Pharmaceuticals's EV-to-EBIT ratio for today is 0.00.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Cancer Prevention Pharmaceuticals's Enterprise Value is $0.00 Mil. Cancer Prevention Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 was $-3.97 Mil. Therefore, Cancer Prevention Pharmaceuticals's EV-to-EBITDA ratio for today is 0.00.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Cancer Prevention Pharmaceuticals's Enterprise Value is $0.00 Mil. Cancer Prevention Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2016 was $1.16 Mil. Therefore, Cancer Prevention Pharmaceuticals's EV-to-Revenue ratio for today is 0.00.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Cancer Prevention Pharmaceuticals's Enterprise Value is $0.00 Mil. Cancer Prevention Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2016 was $0.56 Mil. Therefore, Cancer Prevention Pharmaceuticals's EV-to-FCF ratio for today is 0.00.

Cancer Prevention Pharmaceuticals Enterprise Value Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Enterprise Value Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Enterprise Value

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Enterprise Value	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Cancer Prevention Pharmaceuticals's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Prevention Pharmaceuticals's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's Enterprise Value falls into.

Save Embed

;

Save Embed

;

Cancer Prevention Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Cancer Prevention Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2015 is calculated as

	Enterprise Value (A: Dec. 2015 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	0	+	0	+	0
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	0	+	0	-	1.481
=	-1.48

Cancer Prevention Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2016 is calculated as

	Enterprise Value (Q: Mar. 2016 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	0	+	0	+	5.603
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	0	+	0	-	8.692
=	-3.09

Cancer Prevention Pharmaceuticals (AMEX:CPP) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Cancer Prevention Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-3.976
	=	0.00

Cancer Prevention Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Cancer Prevention Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.98 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Cancer Prevention Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA(TTM)
	=	0.000	/	-3.972
	=	0.00

Cancer Prevention Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Cancer Prevention Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.97 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Cancer Prevention Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	0.000	/	1.159
	=	0.00

Cancer Prevention Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Cancer Prevention Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.16 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Cancer Prevention Pharmaceuticals's EV-to-FCF for today is:

EV-to-FCF	=	Enterprise Value (Today)	/	Free Cash Flow (TTM)
	=	0.000	/	0.555
	=	0.00

Cancer Prevention Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Cancer Prevention Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.56 Mil.

Cancer Prevention Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Enterprise Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.